Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers. The company's lead candidates under development are AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat various tumors, including desmoid tumors; and ADXS-504, a Lm-based therapy for early-stage prostate cancer. Ayala Pharmaceuticals, Inc. was founded in 2017 and is based in Monmouth Junction, New Jersey. Show More...
-
Website https://www.ayalapharma.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 0.03 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-10 2011-10 2012-10 2013-10 2014-10 2015-10 2016-10 2017-10 2018-10 2019-10 TTM Earnings Per Share USD -131.25 -75.0 -74.85 -61.5 -14.55 -25.2 -31.2 -34.65 -19.36 -1.09 -4.0 Dividends USD Payout Ratio % * Shares Mil 1.0 2.0 2.0 3.0 3.0 15.0 27.0 Book Value Per Share * USD -187.22 -92.03 -28.32 -7.35 17.78 43.57 31.32 27.07 7.19 0.98 0.69 Free Cash Flow Per Share * USD -79.16 -77.71 -29.04 -22.19 -18.15 -12.76 -19.43 -15.97 -22.67 -6.75 Return on Assets % -386.88 -226.74 -270.92 -149.93 -70.37 -65.79 -50.97 -71.14 -85.33 -30.9 -73.36 Financial Leverage (Average) 1.31 1.13 1.03 1.42 1.73 2.58 1.14 1.24 Return on Equity % -341.24 -85.55 -69.05 -62.63 -107.67 -169.87 -52.25 -94.34 Return on Invested Capital % -307.45 -85.06 -69.16 -62.9 -108.4 -170.95 -53.62 -81.53 Interest Coverage -1.91 -0.81 -1.74 -19.97 Current Ratio 0.08 0.15 0.1 4.21 7.55 29.36 5.77 3.89 2.21 8.0 9.26 Quick Ratio 0.08 0.14 4.16 7.12 29.08 5.58 3.58 1.93 7.16 8.51 Debt/Equity 0.14